Please ensure Javascript is enabled for purposes of website accessibility

Trump Signs Coronavirus Relief Bill Into Law

By Mark Prvulovic - Updated Mar 19, 2020 at 8:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Senate approved the proposed relief package on Wednesday, with the president signing it shortly after.

After hammering out the details regarding the coronavirus relief package proposed by the Trump administration, the Senate approved the bill on Wednesday, with President Trump signing it into law shortly after.

Although many Republican senators had been critical about the bill, they still emphasized the importance of quickly approving this piece of legislation to help Americans affected by the COVID-19 pandemic. Additionally, a speedy approval of this bill would allow the Senate to focus all its attention on the much larger economic relief package aimed at helping the economy.

A picture of Capital Hill with an American flag flying on a clear sky.

Image source: Getty Images.

This particular bill would bring around $100 billion worth of COVID-19 related aid to Americans, which expands paid leave, unemployment benefits, and mandates free testing for patients suspected of being infected. The vote passed 90-8, with two Republican senators, Rick Scott of Florida and Cory Gardner of Colorado, not voting since they are in self-quarantine after being exposed to people who were COVID-19 positive.

Further details

Coming up on the horizon is a much larger stimulus package meant to help shore up the American economy. Earlier on Wednesday, Treasury Secretary Steve Mnuchin warned that the unemployment rate could spike to 20% if an economic stimulus package of some sort doesn't get approved. Although Democrats and Republicans have different opinions on what it should include, Trump has stated that it would likely feature direct cash payments to Americans. 

Although healthcare companies like Gilead Sciences are working around to clock to develop a COVID-19 treatment of some sort, it's still a way off at this point. Countries that haven't been overwhelmed with patients are preparing for what seems like an inevitable surge of COVID-19 infections in the weeks to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.73 (0.63%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.